ИСПОЛЬЗОВАНИЕ ИНГИБИТОРОВ АПФ ПРИ ЛЕЧЕНИИ ПАРОКСИЗМАЛЬНОЙ ФОРМЫ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ

1. Kannel W., Wolf P., Benjamin E., et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 1998; 82: 2N-9N.

2. Benajmim E., Levy D., Vaziri S., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 171: 840-44.

3. Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика) Санкт-Петербург, 1999. 175 с.

4. Сулимов В.А. Медикаментозная терапия фибрилляции предсердий: настоящее и будущее. Кардиология. 1999; 7: 69-75.

5. ACC/AHA/ESC guidelines for management of patients with atrial fibrillation. Circulation 2001; 104: 2118-2150.

6. Miller J., Zipes D. Management of the patient with cardiac arrhith-mias. A textbook of cardiovascular medicine. Philadelphia: W B. Saunders company; 2001. p. 731-736.

7. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 2003; 41: 2197-204.

8. Li D., Shinagawa K., Pang L. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-2614.

9. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100: 376-380

10. Ueng К.С., Tsai T.P., Yu W.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur. Heart J. 2003; 24: 2090-2098

11. Vermes E., Tardif J.C., Bourassa M.G. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003; 107: 2926-2931.

12. Madrid A.H., Bueno M.G., Rebollo J.M. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336.

13. Jayachandran J.V., Sih H.J., Winkle N., et al. Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation 2000; 101: 1185-1191.

14. Yu W.C. Chen S.A., Lee S.H., et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation 1998; 97: 2331-2337.

15. Zaman A.G., Alamgir F., Richens T. The role of signal averaged P-wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery. Heart 1997; 77: 527-531.

16. Hobbs W.J., Van Gelder I.С., Fitzpatrick A.P., et al. The role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation. J. Cardiovasc. Electrophysiol. 1999; 10: 866-870.

17. Bosch R.F., Zeng X., Grammar J.B., et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc. Res. 1999; 44: 121-131

18. Van Wagoner D.R., Nerbonne J.M. Molecular basis of electrical remodeling in atrial fibrillation. J. Mol. Cell Cardiol. 2000; 32: 1101-1117

19. Nakashima H., Kumagai K., Urata H. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.